Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 8/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3938861 | 1.00 | PARP10 (0.56) | PARP10MAOBMAOAPLA2G4BNPC1 | |
| SCHEMBL3947567 | 0.94 | MAOB (0.56) | PARP10MAOBMAOAPLA2G4BNPC1 | |
| SCHEMBL3948430 | 0.94 | MAOB (0.56) | PARP10MAOBMAOAPLA2G4BNPC1 | |
| SCHEMBL3948433 | 0.94 | MAOB (0.56) | PARP10MAOBMAOAPLA2G4BNPC1 | |
| SCHEMBL3938811 | 0.93 | MAOB (0.56) | PARP10MAOBMAOAPLA2G4BNPC1 | |
| SCHEMBL3938801 | 0.93 | MAOB (0.56) | PARP10MAOBMAOAPLA2G4BNPC1 | |
| SCHEMBL3938809 | 0.93 | MAOB (0.56) | PARP10MAOBMAOAPLA2G4BNPC1 | |
| SCHEMBL3944625 | 0.89 | L3MBTL1 (0.46) | PARP10MAOBMAOAPLA2G4BNPC1 | |
| SCHEMBL3940152 | 0.89 | CYP1A1 (0.59) | PARP10MAOBMAOAPLA2G4BPLK1 | |
| SCHEMBL3940154 | 0.89 | CYP1A1 (0.59) | PARP10MAOBMAOAPLA2G4BPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | PARP10 1526/4885MAOB 747/4885MAOA 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.